STOCK TITAN

State Street discloses 5.5% Intellia Therapeutics (NTLA) ownership stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

State Street Corporation has filed a Schedule 13G reporting beneficial ownership of Intellia Therapeutics common stock. It reports beneficial ownership of 6,418,836 shares, representing 5.5% of the outstanding common stock as of the event date.

State Street reports no sole voting or dispositive power, with shared voting power over 6,045,757 shares and shared dispositive power over 6,418,836 shares. The holdings are reported as being acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Intellia. Several State Street Global Advisors and related investment adviser subsidiaries are identified as relevant entities.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



STATE STREET CORPORATION
Signature:ELIZABETH SCHAEFER
Name/Title:SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
Date:02/09/2026

FAQ

What does State Street Corporation’s Schedule 13G say about its NTLA holdings?

State Street Corporation reports beneficial ownership of 6,418,836 Intellia Therapeutics common shares, representing 5.5% of the class. The position is reported on a Schedule 13G, indicating the shares are held in the ordinary course of business, not to influence control.

How much of Intellia Therapeutics’ common stock does State Street beneficially own?

State Street beneficially owns 6,418,836 Intellia Therapeutics common shares, which equals 5.5% of the outstanding class. This ownership level triggers the requirement to file a Schedule 13G under beneficial ownership rules for significant institutional holders.

What voting and dispositive powers does State Street report over NTLA shares?

State Street reports no sole voting or dispositive power. It reports shared voting power over 6,045,757 Intellia shares and shared dispositive power over 6,418,836 shares, reflecting how its investment adviser affiliates manage these holdings for clients.

Which State Street affiliates are involved in the Intellia Therapeutics position?

The filing identifies several investment adviser subsidiaries, including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd., as relevant entities for the reported holdings.

Why did State Street file a Schedule 13G for Intellia Therapeutics?

State Street filed because its beneficial ownership exceeded 5% of Intellia’s common stock. It certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.

Who signed the State Street Schedule 13G for NTLA and when?

The Schedule 13G was signed by Elizabeth Schaefer, Senior Vice President and Chief Accounting Officer of State Street Corporation. The signature is dated 02/09/2026, certifying that the information in the statement is true, complete, and correct.
Intellia Therape

NASDAQ:NTLA

NTLA Rankings

NTLA Latest News

NTLA Latest SEC Filings

NTLA Stock Data

1.42B
110.44M
4.89%
88.36%
25.84%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States
CAMBRIDGE